[go: up one dir, main page]

MA26289A1 - Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales - Google Patents

Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales

Info

Publication number
MA26289A1
MA26289A1 MA27664A MA27664A MA26289A1 MA 26289 A1 MA26289 A1 MA 26289A1 MA 27664 A MA27664 A MA 27664A MA 27664 A MA27664 A MA 27664A MA 26289 A1 MA26289 A1 MA 26289A1
Authority
MA
Morocco
Prior art keywords
peroxide
prevention
treatment
low concentration
vaginal infections
Prior art date
Application number
MA27664A
Other languages
English (en)
Inventor
William J Bologna
Howard L Levine
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of MA26289A1 publication Critical patent/MA26289A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA27664A 2001-10-29 2004-04-29 Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales MA26289A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33068301P 2001-10-29 2001-10-29
US10/278,910 US7709026B2 (en) 2001-10-29 2002-10-24 Low concentration of peroxide for treating or preventing vaginal infections

Publications (1)

Publication Number Publication Date
MA26289A1 true MA26289A1 (fr) 2004-09-01

Family

ID=26959335

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27664A MA26289A1 (fr) 2001-10-29 2004-04-29 Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales

Country Status (30)

Country Link
US (1) US7709026B2 (fr)
EP (1) EP1441769B1 (fr)
JP (2) JP5153049B2 (fr)
KR (1) KR101009146B1 (fr)
CN (1) CN1578676A (fr)
AR (1) AR037047A1 (fr)
AT (1) ATE297222T1 (fr)
AU (1) AU2002346897B2 (fr)
BR (1) BR0213584A (fr)
CA (1) CA2465133C (fr)
DE (1) DE60204584T2 (fr)
DK (1) DK1441769T3 (fr)
ES (1) ES2243772T3 (fr)
HR (1) HRP20040480B1 (fr)
HU (1) HU229487B1 (fr)
IL (2) IL161512A0 (fr)
MA (1) MA26289A1 (fr)
ME (1) MEP34608A (fr)
MX (1) MXPA04003977A (fr)
MY (1) MY137791A (fr)
NO (1) NO20042199L (fr)
NZ (1) NZ532294A (fr)
PE (1) PE20030492A1 (fr)
PL (2) PL402550A1 (fr)
PT (1) PT1441769E (fr)
RS (1) RS51154B (fr)
RU (1) RU2329829C2 (fr)
SI (1) SI1441769T1 (fr)
WO (1) WO2003037382A1 (fr)
ZA (1) ZA200402943B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
CH697081A5 (de) * 2002-01-22 2008-04-30 Andreas F Dr Schaub Zusammensetzung für die Unterstützung der Geburt eines menschlichen Föten.
US20040126369A1 (en) * 2002-12-30 2004-07-01 Richard Payne Delivery of peroxide-generating enzymes to the vaginal tract
DE10328942A1 (de) * 2003-06-27 2005-01-27 Lts Lohmann Therapie-Systeme Ag Transmukosale Darreichungsformen mit verminderter Schleimhautirritation
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
US20050276865A1 (en) * 2004-05-20 2005-12-15 Servet Buyuktimkin Peroxide compounds for the prevention and treatment of sexual dysfunction in humans
DE102004054552A1 (de) * 2004-11-11 2006-05-18 Hcb Happy Child Birth Holding Ag Neue Zusammensetzung zur Erleichterung der Humangeburt
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
US20120074014A1 (en) * 2010-09-27 2012-03-29 Lutran Industries, Inc. Product typically based on salt of peroxymonosulfuric acid and suitable for medicinal usage, and associated product fabrication
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US9895311B2 (en) 2014-09-25 2018-02-20 Pharmiva Ab Foam-forming compositions and methods for delivering an active to a body cavity
RU2019134342A (ru) * 2017-03-30 2021-04-28 Сайнтелл, Ллк Способ лечения и предупреждения инфекций
HUE062093T2 (hu) 2017-05-23 2023-09-28 Pharmiva Ab Hatóanyag testüreghez juttatására szolgáló, habképzõ készítmények
WO2020084548A1 (fr) * 2018-10-26 2020-04-30 Viramal Limited Composition de gel mucoadhésif
US11850303B2 (en) * 2020-10-27 2023-12-26 Uqora, Inc. Gel and a suppository and methods to provide the gel and suppository
WO2024231498A1 (fr) * 2023-05-09 2024-11-14 BioNTech SE Formulations intravaginales de gardnerella endolysines
WO2025125456A1 (fr) * 2023-12-12 2025-06-19 BioNTech SE Compositions comprenant une endolysine et leurs utilisations
WO2025217642A1 (fr) * 2024-04-12 2025-10-16 The General Hospital Corporation Système et méthode de traitement des infections et de l'inflammation vaginales

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
BE535125A (fr) 1954-01-25
NL108604C (fr) 1957-08-27
US4127515A (en) * 1974-10-21 1978-11-28 Colgate-Palmolive Company Waxing sponge
US4607101A (en) * 1981-08-27 1986-08-19 Jaye-Boern Laboratories, Inc. Method of treating acne vulgaris with a composition containing carbamide peroxide
AU565354B2 (en) * 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
GB8505402D0 (en) * 1985-03-02 1985-04-03 Ciba Geigy Ag Modified phenolic resins
US4657935A (en) * 1985-07-22 1987-04-14 Carlos Teplicki Real acne control (RAC)
US4923677A (en) 1985-08-07 1990-05-08 Roy T. Witkin Chemical sterilization
US4997625A (en) 1985-08-07 1991-03-05 Simon Gilbert I Chemical sterilization
US4670256A (en) 1985-09-23 1987-06-02 V. Valhalla Corp. Vaginal conditioning for sexual activity
US4781923A (en) * 1987-07-20 1988-11-01 Pellico Michael A Antiseptic gels
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US6017521A (en) * 1989-10-31 2000-01-25 Columbia Laboratories, Inc. Use of polycarboxylic acid polymers to treat vaginal infections
US5376006A (en) 1990-03-22 1994-12-27 Ultradent Products, Inc. Dental bleaching compositions and methods for bleaching teeth surfaces
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5340836A (en) 1991-02-19 1994-08-23 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
US5573765A (en) 1991-02-19 1996-11-12 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
IL97930A (en) * 1991-04-23 1996-06-18 Perio Prod Ltd Preparations for whitening two controlled release products that contain a super-oxygen compound
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5571533A (en) * 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
US5667817A (en) 1992-03-20 1997-09-16 Alcide Corporation Method and composition for prevention and treatment of female lower genital tract microbial infections
US5898037A (en) 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5489435A (en) 1993-07-06 1996-02-06 Ratcliff; Perry A. Composition for treatment of abnormal conditions of the epithelium of bodily orifices
US6200557B1 (en) 1993-07-06 2001-03-13 Perry A. Ratcliff Method of treating HIV by a topical composition
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
UA39965C2 (uk) 1993-12-03 2001-07-16 Лайфор Леборетріз Лтд Вірусоцидний, бактерицидний та руйнуючий сперматозоїди вагінальний засіб і вагінальний супозиторій ( варіанти )
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
US5741525A (en) 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
SI0869772T1 (en) * 1995-12-27 2002-04-30 Janssen Pharmaceutica N.V. Bioadhesive solid dosage form
US5778886A (en) 1996-02-27 1998-07-14 Shihata; Alfred Vaginal compositions combining a spermicidal agent and a peroxygen compound
US5819742A (en) 1996-11-06 1998-10-13 Family Health International Vaginal device for preventing conception or the transmission of sexually transmitted diseases, or both
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
US5843998A (en) * 1997-06-30 1998-12-01 Song; Jin Skin blemish treatment
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6117859A (en) * 1997-11-04 2000-09-12 The Research Foundation Of State University Of New York Method of relieving chronic inflammation by using 5-alkylsulfonylsalicylanilides
CA2335055A1 (fr) 1998-06-19 1999-12-23 Jack Fellman Dispositif medical a proprietes anti-infectieuses et contraceptives
US6277363B1 (en) 1998-09-21 2001-08-21 Vortech, Inc. Method and composition for treating chlamydia infection
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
EP1267826B1 (fr) 1999-10-22 2007-01-03 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Composition pharmaceutique pour le traitement de l'ulceration et/ou erosion epitheliale des muqueuses
US6200551B1 (en) 2000-01-27 2001-03-13 Susan Ann Morgan Treatment for dry mouth employing carbamide peroxide
US6235314B1 (en) * 2000-08-08 2001-05-22 Sarfaraz K. Niazi Analgesic, anti-inflammatory and skeletal muscle relaxant compositions
MXPA03002891A (es) * 2000-10-02 2003-10-15 Univ New York State Res Found Naftilsalicilaniluros como agentes antiinflamatorios y antimicrobianos.
US20030211173A1 (en) 2002-05-08 2003-11-13 Veach Tom C. Lubrication composition
US7049000B2 (en) * 2003-08-06 2006-05-23 The Procter & Gamble Company Water-swellable material comprising coated water-swellable polymers
US20090156672A1 (en) * 2007-12-17 2009-06-18 Northwestern University Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities

Also Published As

Publication number Publication date
WO2003037382A1 (fr) 2003-05-08
HK1063290A1 (en) 2004-12-24
BR0213584A (pt) 2004-08-24
US7709026B2 (en) 2010-05-04
HRP20040480A2 (en) 2004-10-31
MEP34608A (en) 2011-02-10
RU2329829C2 (ru) 2008-07-27
KR101009146B1 (ko) 2011-01-18
NZ532294A (en) 2006-12-22
HRP20040480B1 (hr) 2007-11-30
AR037047A1 (es) 2004-10-20
HUP0401672A3 (en) 2008-04-28
HU229487B1 (en) 2014-01-28
PL369725A1 (en) 2005-05-02
DK1441769T3 (da) 2005-09-12
IL161512A (en) 2009-07-20
JP2010248232A (ja) 2010-11-04
PL402550A1 (pl) 2013-08-05
ATE297222T1 (de) 2005-06-15
PT1441769E (pt) 2005-08-31
MY137791A (en) 2009-03-31
RS36604A (sr) 2006-12-15
DE60204584T2 (de) 2006-03-16
US20030091644A1 (en) 2003-05-15
HUP0401672A2 (hu) 2005-07-28
JP5153049B2 (ja) 2013-02-27
JP2005510505A (ja) 2005-04-21
NO20042199L (no) 2004-05-26
EP1441769B1 (fr) 2005-06-08
PL216746B1 (pl) 2014-05-30
CA2465133A1 (fr) 2003-05-08
SI1441769T1 (sl) 2005-12-31
MXPA04003977A (es) 2004-07-08
CA2465133C (fr) 2012-03-06
ES2243772T3 (es) 2005-12-01
ZA200402943B (en) 2005-03-30
IL161512A0 (en) 2004-09-27
DE60204584D1 (de) 2005-07-14
RU2004116312A (ru) 2005-04-10
EP1441769A1 (fr) 2004-08-04
AU2002346897B2 (en) 2008-04-17
KR20050056903A (ko) 2005-06-16
CN1578676A (zh) 2005-02-09
RS51154B (sr) 2010-10-31
PE20030492A1 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
MA26289A1 (fr) Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales
EP1390029A4 (fr) Phenylindoles pour le traitement de l'infection par le vih
MA25775A1 (fr) Combinaison des bacteries d'acide lactique et son utilisation pour la prevention et/ou le traitement des infections et des etats inflammatoires.
MA25823A1 (fr) Compositions pour le traitement de l'eau.
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
EP1442047A4 (fr) Nouvelle compositions immunogenes utilisees pour la prevention et le traitement de la meningococcie
MA26207A1 (fr) Compositions de traitement de l'eau.
EP1536804A4 (fr) Ester 3'-l-valine de ?-d-2'-c-methyl-ribofuranosyl cytidine pour le traitement d'infections par des flaviviridae
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
DZ1877A1 (fr) Forme posologiques d'azithromycine pour le traitement d'infection microbiennes.
SE0102315D0 (sv) Compounds
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
DE60022916D1 (de) Reboxetin zur Behandlung von peripheren Neuropathien
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
EP1453505A4 (fr) Utilisation de pramipexole pour traiter la sclerose laterale amyotrophique
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
MA26896A1 (fr) Utilisation de compositions d'antibiotiques azalides pour le traitement ou la prevention d'une infection par des bacteries ou protozoaires chez des mammiferes
EP1037650A4 (fr) Procedes et compositions pour le traitement et la prevention d'infections a staphylococcus aureus
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
EP1161255A4 (fr) Procedes et compositions pour le traitement de la dyserection
MA25501A1 (fr) Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
EP1547594A4 (fr) Prevention ou traitement d'escarres de decubitus